Search

Your search keyword '"Gregersen, Henrik"' showing total 339 results

Search Constraints

Start Over You searched for: Author "Gregersen, Henrik" Remove constraint Author: "Gregersen, Henrik"
339 results on '"Gregersen, Henrik"'

Search Results

1. Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

2. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

4. Strategies to improve patient-reported outcome completion rates in longitudinal studies

6. P-050 GEN3014 (HexaBody-CD38) versus daratumumab in patients with relapsed/ refractory multiple myeloma: design of randomized head-to-head expansion cohort of phase 1/2 trial

7. P817: VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2-ISS) IN A LARGE POPULATION-BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

8. P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

11. Geographical and ecological analyses of multiple myeloma in Denmark:Identification of potential hotspot areas and impact of urbanisation

12. Dansk Myelomatose Database – Resumé af årsrapport 2021

13. Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation

14. Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

15. Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody (R)-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

16. A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

17. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

18. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group

19. Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries

20. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma:A randomised phase 2 trial by the Nordic Myeloma Study Group

21. Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation.

22. Additional file 1 of Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission ��� results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

23. The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey

24. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

25. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group

26. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system

27. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic

28. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

29. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database

33. Dansk Myelomatose Database:Årsrapport 2020

34. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

35. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry

36. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic

37. Can missing PRO data be handled appropriately by last observation carried forward (LOCF)?

38. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

39. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

43. Comorbidities in multiple myeloma and implications on survival: A population‐based study

44. Monoklonal gammopati med ubestemt signifikans

48. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry

50. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Catalog

Books, media, physical & digital resources